

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Moxifloxacin Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 26 Talavera Road, Talavera Corp Centre, Macquarie Park
New South Wales, 2113 Australia

Telephone : (61)-02-8988-8000

Emergency telephone number : (61)-02-8988-8000

E-mail address : EHSDATASTEWARD@msd.com

Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure : Category 2 (Liver)

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H302 Harmful if swallowed.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Liver) through prolonged or repeated exposure.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
 Date of first issue: 05.06.2017

P281 Use personal protective equipment as required.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth.
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 40 -<= 70
Cellulose	9004-34-6	>= 10 -<= 30

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
 Remove contaminated clothing and shoes.
 Get medical attention.
 Wash clothing before reuse.
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
 If easy to do, remove contact lens, if worn.
 Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention.
 Rinse mouth thoroughly with water.
 Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
 Suspected of damaging the unborn child.
 May cause damage to organs through prolonged or repeated exposure.

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
1.5	09/13/2019	1731671-00006	Date of first issue: 05.06.2017

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not swallow.
Do not get in eyes.

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
 Date of first issue: 05.06.2017

- Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
 Store locked up.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m ³ (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	AU OEL
Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica				
		TWA	10 mg/m ³	ACGIH

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection : Chemical-resistant gloves
- Material
- Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
1.5	09/13/2019	1731671-00006	Date of first issue: 05.06.2017

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	solid
Colour	:	pink
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,886 mg/kg
Method: Calculation method

Components:**Moxifloxacin HCL:**

Acute oral toxicity : LD50 (Rat): 1,320 mg/kg
LD50 (Mouse): > 435 mg/kg
LD50 (Monkey): 1,500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

Components:**Moxifloxacin HCL:**

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Moxifloxacin HCL:**

Species : Rabbit
Result : Moderate eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: in vitro micronucleus test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Application Route: Oral
Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
1.5	09/13/2019	1731671-00006	Date of first issue: 05.06.2017

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 500 mg/kg body weight
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Monkey
Application Route: Oral
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 20 mg/kg body weight
Symptoms: Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion

Moxifloxacin Solid Formulation

Version 1.5 Revision Date: 09/13/2019 SDS Number: 1731671-00006 Date of last issue: 24.04.2019
Date of first issue: 05.06.2017

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver) through prolonged or repeated exposure.

Components:**Moxifloxacin HCL:**

Target Organs : Liver
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Moxifloxacin HCL:**

Species : Rat
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver
Symptoms : Liver disorders

Species : Rat
NOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : Liver
Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Symptoms : No adverse effects

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Gastrointestinal tract
Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
1.5	09/13/2019	1731671-00006	Date of first issue: 05.06.2017

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION**Further information**

Revision Date : 09/13/2019
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 24.04.2019
1.5	09/13/2019	1731671-00006	Date of first issue: 05.06.2017

AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average

AU OEL / TWA : Exposure standard - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN